Abstract
The incidence of adenocarcinoma of esophagogastric junction is increasing worldwide during the past decades. Issues such as TNM classification, surgical approach, extent of lymphadenectomy, digestive tract reconstruction and perioperative adjuvant treatment remain unsolved. The debates on surgical approach and splenectomy have reached a consensus according to the results of clinical trials, but most of the controversy are waiting for the final outcomes of randomized trials. Key words: Esophagogastric junction neoplasms, adenocarcinoma; Diagnosis; Therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
